Tripos, Nasdaq, Cambridge University, Rescentris, Columbus Children's Research Institute, Biomatters, KAREN | GenomeWeb
Tripos Receives Nasdaq Delisting Notification, New Offer for Discovery Research Business
Tripos said this week that it faces delisting for non-compliance with the Nasdaq Global Market’s minimum $10 million stockholders' equity requirement.
Separately, the company announced that it entered into a material agreement to sell its Discovery Research business to Commonwealth Biotechnologies, a molecular diagnostics company based in Richmond, Va.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.